NCT00449176: A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain |
|
|
| Completed | 3 | 981 | US | tapentadol (CG5503) ER, oxycodone CR, placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Grünenthal GmbH | Low Back Pain | 05/08 | 05/08 | | |
NCT00361504: A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain |
|
|
| Completed | 3 | 1123 | US, Canada | Oxycodone CR, Tapentadol (CG5503) ER, CG5503 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Grünenthal GmbH | Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain, Pain | 07/08 | 07/08 | | |
NCT01427283 / 2011-005061-20: A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain |
|
|
| Completed | 3 | 450 | US | Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, OxyContin, Placebo | Purdue Pharma LP | Low Back Pain | 10/14 | 10/14 | | |
NCT01427270 / 2011-005060-26: Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain |
|
|
| Completed | 3 | 455 | Europe, US | Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, OxyContin, Placebo | Purdue Pharma LP | Low Back Pain | 10/14 | 10/14 | | |
